Top > Search of International Patents > ANTIGEN COMPOSITION

ANTIGEN COMPOSITION meetings

Foreign code F190009735
File No. (170012JP01,S2017-0684-N0)
Posted date Apr 25, 2019
Country WIPO
International application number 2018JP029395
International publication number WO 2019031446
Date of international filing Aug 6, 2018
Date of international publication Feb 14, 2019
Priority data
  • P2017-152123 (Aug 7, 2017) JP
Title ANTIGEN COMPOSITION meetings
Abstract [Problem] To provide a method and a composition for enhancing the immunogenicity of a polypeptide.
[Solution] Provided is a composition containing a tagged polypeptide which is composed of a polypeptide, a spacer peptide bonded to a terminal of the polypeptide and composed of 0 to 2 amino acid residues, and a tag peptide bonded to the spacer peptide and composed of 3 to 12 amino acid residues, wherein the tag peptide is composed of Ile, Val, Lys, Arg, Asn, Asp, Ser, Leu, Ala, His, Pro or a combination thereof.
Outline of related art and contending technology BACKGROUND ART
Antibody production is, as a result of the antigen stimulus, in vivo immune response induced in the animal. Therefore, a certain type of antigenic polypeptide (or protein) is, by inducing the production of antibodies to it, preventing an infection by a virus or a bacterium of the invention is not limited to, treatment or prevention of cancer or the like is used as a vaccine used. In addition, certain types of antigen polypeptide is, in a non-human animal for producing monoclonal antibodies and antisera are utilized.
However, all of the antigenic polypeptide is sufficient to induce antibody production in vivo but may not be known. For example, several tens of amino acids-the order of several ten to several hundred in a relatively small residues of the polypeptide immunogenicity often weak in general are known. Therefore, such a weak polypeptide immunogenicity when used to immunize an animal, in order to enhance its immunogenicity often adjuvant is administered at the same time.
However, on the other hand, for such purposes, a general-purpose complete Freund's experimental animals, Freund's adjuvant (Complete Freund's adjuvant) and, adjuvant (Freund's adjuvant) is, the potential side effects to humans for use are limited. Therefore, without the use of an adjuvant polypeptide immunogenicity to enhance the immunogenicity of weak sufficiently to induce antibody production is demanded.
The inventors of the present invention, first, the end of the polypeptide from the hydrophilic amino acids of 1-20 by applying the tag to improve the solubility of the polypeptide can be found (Patent Document 1). In addition, the inventors of the present invention, any biological molecule at the end of the peptide comprising the amino acid sequence of peptide is added to the additional thermodynamic solubility of the molecules of a living body based on the theory and the method for calculating the solubility of the desired calculation method and the method of designing a peptide, using such methods as well as inclusion bodies (E. coli with the recombinant cells or the like stored in the aggregation in the non-active) are found a method of preventing the formation of (Patent Document 2). However, any of the preceding documents, the end of the polypeptide comprising the amino acid of the specific tagged tag is added to the polypeptide, the polypeptide will be obtained to enhance the immunogenicity and, does not disclose or suggest.
Scope of claims (In Japanese)請求の範囲 [請求項1]
 抗原ペプチド、該抗原ペプチドの末端に結合した0~2個のアミノ酸で構成されるスペーサー・ペプチド及び該スペーサー・ペプチドに結合した3~12個のアミノ酸で構成されるタグ・ペプチドから成り、該タグ・ペプチドはIle、Val、Lys、Arg、Asn、Asp、Ser、Leu、Ala、His、Proまたはそれらの組合せから構成されることを特徴とするタグ化ポリペプチドを含む、前記抗原ペプチドに対する抗体を生産するための抗原組成物。

[請求項2]
 前記タグ・ペプチドを構成するアミノ酸がIle、Lys、Arg、Asn、Asp、Ala、HisまたはProである、請求項1に記載の抗原組成物。

[請求項3]
 前記タグ・ペプチドが4~6個のアミノ酸で構成される、請求項1又は2に記載の抗原組成物。

[請求項4]
 前記スペーサー・ペプチドを構成するアミノ酸がGlyまたはSerである、請求項1~3のいずれか一項に記載の抗原組成物。

[請求項5]
 前記スペーサー・ペプチドが2個のアミノ酸で構成される、請求項1~4のいずれか一項に記載の抗原組成物。

[請求項6]
 前記抗原ペプチドのC末端にスペーサー・ペプチドが結合する、請求項1~5のいずれか一項に記載の抗原組成物。

[請求項7]
 前記抗原ペプチドがデング熱ウイルスDEN3-ED3タンパク質である、請求項1~6のいずれか一項に記載の組成物。

[請求項8]
 生理学的に許容される担体を含むワクチンの形態である、請求項1~7のいずれか一項に記載の抗原組成物。

[請求項9]
 更にアジュバントを含む、請求項1~8のいずれか一項に記載の抗原組成物。

[請求項10]
 動物を免疫する方法であって、免疫有効量の請求項1~9のいずれか一項に記載の抗原組成物を該動物に投与することを含む、前記方法。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY
  • Inventor
  • KURODA Yutaka
  • KAMIOKA Tetsuya
  • RAHMAN Nafsoon
  • ISLAM Monirul Mohammad
  • MIURA Shiho
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close